Sudeep Pharma (SUDEEPPHRM) Q3 25/26 earnings summary

Executive summary

• Achieved 52% year-over-year revenue growth in Q3 FY26, with EBITDA and PAT up 60% and 66% respectively, driven by robust demand across business segments.

• Completed IPO in Q3 FY26, listing on NSE and BSE on 28 Nov 2025, raising net proceeds of INR 8,833.59 lakhs from fresh issue and OFS.

• Strategic developments included the groundbreaking of a battery chemicals plant and integration of the NSS acquisition, expanding advanced formulation capabilities and global reach.

• Acquired 85% equity in Nutrition Supplier & Services (Ireland) Ltd, making it a step-down subsidiary from May 2025.

• Early commercial orders for advanced materials and capacity upgrades signal initial customer adoption in new segments.

Financial highlights

• Q3 FY26 total income reached Rs 179.2 Cr, up 52% YoY; 9MFY26 total income at Rs 482.1 Cr, up 38% YoY.

• Q3 FY26 EBITDA was Rs 66.8 Cr (37.3% margin), up 60% YoY; PAT was Rs 47.7 Cr (26.6% margin), up 66% YoY.

• EPS for Q3 FY26 stood at 4.29, up from 2.65 YoY; 9MFY26 EPS at 11.32.

• Consolidated revenue from operations for Q3 FY26: INR 17,233.56 lakhs, up from INR 11,553.81 lakhs in Q3 FY25.

• Historical FY25 revenue was Rs 502.0 Cr, with PAT of Rs 138.7 Cr and EBITDA margin of 39.0%.

Outlook and guidance

• Greenfield manufacturing facility at Nandesari expected to be commissioned by Q4 FY26.

• Battery chemicals plant at Dahej (Phase I: 25,000 MT) targeted for completion by early CY27, with global expansion plans in battery materials.

• IPO proceeds allocated to capital expenditure for machinery and general corporate purposes; unutilized funds held in term deposits.

• Management expects sustained growth, leveraging expanding product portfolio and investments in high-growth segments.

• Management continues to monitor regulatory changes, including new Indian labour codes, with no material impact expected.